Synthetic Thymosin Beta-4 (Tβ4) Fragment
A synthetic version of the naturally occurring Thymosin Beta-4 protein found in virtually all human cells. TB-500 operates primarily through actin regulation, the protein responsible for cell movement, structure, and migration, making it a foundational compound in cellular repair and regeneration.
01, Research Summary
TB-500 has developed a substantial research portfolio across multiple domains. The evidence base spans animal models, cell studies, and in some cases early human data, providing a multi-layered picture of this compound's mechanisms and potential applications.
Post-infarction cardiac repair. TB-500 administered following experimental myocardial infarction in rodent models demonstrated significant improvement in cardiac muscle survival, reduced scar formation, and improved heart function.
Corneal wound healing. TB-500 accelerated corneal re-epithelialization in human-relevant models, modulating cytokine expression and reducing inflammatory infiltration, supporting its anti-inflammatory and pro-healing dual action.
Skeletal muscle regeneration. Studies confirm TB-500 promotes satellite cell activation and muscle fibre repair following acute injury, with significantly faster functional restoration compared to controls.
Fibrosis reduction. TB-500 inhibits TGF-β1-mediated fibroblast activation, reducing the deposition of excess collagen that leads to scar tissue. This anti-fibrotic action distinguishes it from compounds that promote indiscriminate collagen production.
Actin-binding established. Landmark research confirmed TB-500's role as the body's primary G-actin sequestering peptide. By binding actin monomers, it regulates the polymerisation/depolymerisation balance essential for cell movement and repair.
02, Mechanism of Action
Understanding the mechanism helps explain why TB-500 produces the range of effects documented in both research and community reports. The compound operates through several interconnected pathways simultaneously.
TB-500 binds G-actin (monomeric actin) with high affinity, acting as the body's primary actin buffer. By regulating the pool of available actin, it controls the dynamic balance between F-actin filaments and free G-actin, the molecular machinery of cell movement.
Through actin regulation, TB-500 dramatically enhances the migratory capacity of fibroblasts, keratinocytes, endothelial cells, and immune cells. Faster cell migration to injury sites accelerates every phase of tissue repair.
TB-500 downregulates NF-κB signalling and reduces MMP (matrix metalloproteinase) activity, two key drivers of chronic inflammation and tissue degradation. This shifts the tissue environment from destructive inflammation toward productive repair.
Like BPC-157, TB-500 upregulates VEGF expression, promoting new blood vessel formation at injury sites. When stacked with BPC-157, their VEGF-upregulating effects appear additive rather than redundant.
By inhibiting TGF-β1 and modulating myofibroblast differentiation, TB-500 reduces fibrotic scar formation. This is particularly valuable for chronic injuries where fibrosis is limiting recovery, tendons, heart muscle, and liver tissue.
The multi-pathway mechanism of TB-500 explains its broad range of documented effects. Rather than acting on a single target, it engages multiple biological systems simultaneously, which is both the source of its versatility and the reason dosing and cycling matter.
03, Dosing Protocols
The following protocols are drawn from published research literature and community-reported experience. Individual responses vary significantly. Always start at the lower end of the dose range.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Loading phase | 4–7.66 mg | 2× per week | 4–6 weeks | Higher initial dose to saturate tissue. Split across 2 injections per week. |
| Maintenance phase | 2–2.5 mg | 2× per week | Ongoing | Lower dose to maintain tissue levels after loading. Common in athlete protocols. |
| Injury-specific | 5 mg | 2× per week | Until resolved | Higher dose concentrated around acute injury. Often stacked with BPC-157. |
| Preventative | 1–2 mg | 1× per week | Ongoing | Low-dose maintenance for connective tissue health. Popular in high-volume training athletes. |
Reconstitution: Add 1–2 mL bacteriostatic water per vial. Swirl gently. Store refrigerated at 2–8°C, use within 28 days. Loading vs maintenance: Most protocols use a 4–6 week loading phase at higher doses, then reduce to a maintenance dose. TB-500 has a longer half-life than BPC-157, so less frequent injection is required.
All dosing information is drawn from published research and community protocols for educational purposes only. TB-500 is not FDA-approved for human therapeutic use. Consult a licensed healthcare professional before initiating any peptide protocol.
04, Community Experiences
TB-500 has earned consistent high regard in the peptide community, particularly among athletes and older users dealing with chronic injuries. It is almost universally discussed alongside BPC-157, the Wolverine stack is referenced more than any other peptide combination across r/Peptides. The following links surface real discussions from public research and wellness communities. These are anecdotal reports, not clinical evidence, and results vary significantly between individuals.
These are user-reported experiences from public forums. They are not endorsed by Whats That Peptide and should not be interpreted as clinical evidence of efficacy or safety. Individual results vary. Always consult a healthcare professional before starting any peptide protocol.
"I had a shoulder that had been limited to about 70% range of motion for 3 years. Physio, cortisone, rest, nothing worked. 6 weeks of TB-500 and I'm back to full range. I genuinely cannot explain it any other way..."
"The synergy between these two is real. BPC handles the signalling and angiogenesis. TB-500 handles cell movement and anti-fibrosis. Together they cover every phase of the healing cascade. This is the most evidence-based peptide stack available..."
"My cardiologist reviewed the cardiac repair literature and said the preclinical data was compelling. He's not prescribing it but he's not telling me to stop. My echo at 6 months was better than expected..."
"Ran TB-500 alone for first 6 weeks, added BPC-157 for second 6 weeks. The combination was noticeably more effective for my knee. TB-500 alone did something, the stack did more. Would not run either without the other again..."